Clinical Trials · NCT01178996
Thymosin Alpha-1 in Combination With Peg-Interferon Alfa- 2a and Ribavirin for the Therapy of Chronic Hepatitis C Nonresponsive to the Combination of IFN and Ribavirin.
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- sigma-tau i.f.r. S.p.A.
- Enrollment
- 552
- Start date
- Dec 2004
- Locations
- 9 sites, 5 countries
- Primary endpoint
- Sustained Virological Response (SVR)